Cognition Therapeutics, Inc. announced on June 24, 2026, that it received written feedback from the U.S. Food and Drug Administration (FDA) following a meeting held in May 2026. The company is a clinical-stage biopharmaceutical company focused on developing therapies for neurodegenerative diseases.